Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06546033

Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis

Determination of the Effects of Intermittent Fasting and Mediterranean Diet on Quality of Life, Circadian Rhythm and Appetite Markers in Patient With Multiple Sclerosis

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
34 (estimated)
Sponsor
Nigde Omer Halisdemir University · Academic / Other
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

When the literature was reviewed, there is no study in which the effects of intermittent fasting and Mediterranean diet on quality of life, sleep, circadian rhythm and appetite hormones leptin and ghrelin levels in MS patients were evaluated and the two diet types were comparatively examined in terms of all these parameters.

Detailed description

Multiple Sclerosis (MS) is the most common chronic inflammatory disease affecting young adults between the ages of 20-40 years, which causes irreversible neurological damage and symptoms and is influenced by genetic and environmental factors on the Central Nervous System. Depression that may occur in MS patients leads to decreased motivation and negatively affects the quality of life. At the same time, depression may be accompanied by sleep disorders, anxiety, fatigue and eating disorders. Nutrition is recognised as one of the possible risk factors for the development of MS and has potential applications in the management and treatment of the disease. When the literature was reviewed, there is no study evaluating the effect of intermittent fasting and Mediterranean diet on quality of life, sleep, circadian rhythm and appetite hormones leptin and ghrelin levels in MS patients and comparing the two diet types in terms of all these parameters.

Conditions

Interventions

TypeNameDescription
OTHERapplication of different types of dietapplication of different types of diet

Timeline

Start date
2024-05-02
Primary completion
2026-09-02
Completion
2026-12-02
First posted
2024-08-09
Last updated
2024-08-09

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06546033. Inclusion in this directory is not an endorsement.